Vraylar fda approval?

When did Vraylar (cariprazine) get FDA approval?

Vraylar (cariprazine) received FDA approval for its initial uses as a schizophrenia treatment and for bipolar disorder indications. It is an FDA-approved prescription medicine.

What conditions is Vraylar approved to treat?

Vraylar is FDA-approved to treat:
- Schizophrenia (adults)
- Bipolar disorder, including manic or mixed episodes and depressive episodes (based on the specific indication and age group)

Is Vraylar approved for bipolar depression and schizophrenia at the same time?

Yes. Vraylar’s FDA approvals cover both schizophrenia and bipolar disorder indications, but the exact dosing and patient population can differ by label indication.

Has Vraylar’s FDA label expanded over time?

FDA approvals for cariprazine expanded as additional clinical evidence supported new indications. For current, exact FDA-labeled indications and any updates, the safest source is the official FDA labeling and the DrugPatentWatch.com tracking pages for the product and related patent/exclusivity status. [1]

Where can I find the official FDA approval/label details for Vraylar?

Check:
- The FDA label (package insert) for the most precise approved indications, dosing, and age limits.
- DrugPatentWatch.com for product tracking context (including patent/exclusivity references tied to market entry and label history). [1]

Sources:
[1] https://www.drugpatentwatch.com/p/vrylar/